Background: In the treatment of patients with hypertension and dyslipidemia, great attention has been devoted to hypolipidemic diet, graduated exercise and statins. Accordingly, a complex application of non-medication and statins to those patients is concerned in weakening of regular blood elements' aggregative ability. This study aims to establish the complex impact of rosuvastatin and nonmedicinal therapy on aggregative features of regular blood elements in patients with arterial hypertension and dyslipidemia.
Materials and Methods: There were 61 patients with grade I-II of hypertension, risk 3 with dyslipidemia of IIb type. All the patients were prescribed rosuvastatin, hypolipidemic diet, and graduated exercise. Enalapril 10 mg twice a day was given for hypotension. Registration of clinical and laboratory indices was made in 6, 12, 18, 52 and 104 weeks of therapy. Biochemical, hematological, and statistical methods of investigation were applied. There were 26 healthy volunteers as a control group.
Results: This study show a surplus aggregation of erythrocytes (aggregates' quantity rose to 44,4%), platelets (with ADP on 74,5%; with collagen - on 48,2%) and neutrophils (with lectin on 55,8%; with phytohemagglutinin - on 38,2%). During 104 weeks of therapy, it suggested a positively influenced lipid composition and level of lipid peroxidation in plasma as well as regular blood elements taking the given indices on the control level for 6 weeks. Fulfilled therapy show a normalized erythrocytes' aggregative abilities (aggregates' quantity decreased on 44,4%), platelets' aggregation (inhibited with ADP on 74,8%, with collagen - on 47,8%), and neutrophils (aggregation weakened with lectin on 55,8%, with phytohemagglutinin - on 38,2%) during 6 weeks. Reached results were kept in patients until the end of the investigation.
Conclusion: Rosuvastatin intervention give normalizes lipid composition and level of lipid peroxidation in plasma as well as regular blood elements for 6 weeks of study. In addition, it is also lowering erythrocytes' aggregative abilities as well as platelets and neutrophils during for 6 weeks of therapy.